4.5 Article

Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2019.0059

关键词

-

类别

资金

  1. AstraZeneca
  2. Celgene Corporation
  3. Clovis Oncology
  4. Eisai
  5. Genentech
  6. Genomic Health, Inc.
  7. Novartis
  8. Taiho Oncology, Inc.
  9. TESARO
  10. AbbVie
  11. Amgen
  12. Gilead Sciences, Medical Affairs

向作者/读者索取更多资源

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as preferred interventions, whereas others are categorized as either other recommended interventions or useful under certain circumstances.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据